Increased cerebrospinal fluid osteopontin levels and its involvement in macrophage infiltration in neuromyelitis optica

BBA Clinical

Volumn 3, Issue , 2015, Pages 126-134

  Kariya, Yoshinobu ^a   Kariya, Yukiko ^a   Saito, Toshie ^a   Nishiyama, Shuhei ^b   Honda, Takashi ^a   Tanaka, Keiko ^c   Yoshida, Mari ^d   Fujihara, Kazuo ^b   Hashimoto, Yasuhiro ^a  

^a FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

^b TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c KANAZAWA MEDICAL UNIVERSITY   (Japan)

^d AICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

Biomarker; Cerebrospinal fluid; Integrin; Multiple sclerosis; Neuromyelitis optica; Osteopontin

Indexed keywords

CD51 ANTIGEN; HERMES ANTIGEN; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; OSTEOPONTIN; PHOSPHATIDYLINOSITOL 3 KINASE;

ADULT; ARTICLE; ASTROCYTE; CELL INFILTRATION; CELL LYSATE; CELL MIGRATION ASSAY; CEREBROSPINAL FLUID ANALYSIS; CHEMOTAXIS ASSAY; CLINICAL ARTICLE; DEPHOSPHORYLATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; KRUSKAL WALLIS TEST; MACROPHAGE INFILTRATION; MALE; MULTIPLE SCLEROSIS; MYELOOPTIC NEUROPATHY; OLIGODENDROGLIA; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; WESTERN BLOTTING; WHITE MATTER;

EID: 84921474502     PISSN: 22146474     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbacli.2015.01.003     Document Type: Article

References (30)

1. Axtell R.C., Raman C., Steinman L. Interferon-beta exacerbates Th17-mediated inflammatory disease. Trends Immunol. 2011, 32:272-277.
2. Axtell R.C., de Jong B.A., Boniface K., van der Voort L.F., Bhat R., De Sarno P., Naves R., Han M., Zhong F., Castellanos J.G., Mair R., Christakos A., Kolkowitz I., Katz L., Killestein J., Polman C.H., de Waal Malefyt R., Steinman L., Raman C. T helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis. Nat. Med. 2010, 16:406-412.
3. Bellahcene A., Castronovo V., Ogbureke K.U., Fisher L.W., Fedarko N.S. Small integrin-binding ligand N-linked glycoproteins (SIBLINGs): multifunctional proteins in cancer. Nat. Rev. Cancer 2008, 8:212-226.
4. Bornsen L., Khademi M., Olsson T., Sorensen P.S., Sellebjerg F. Osteopontin concentrations are increased in cerebrospinal fluid during attacks of multiple sclerosis. Mult. Scler. 2011, 17:32-42. (Epub 2010 Oct 2014).
5. Briggs T.A., et al. Tartrate-resistant acid phosphatase deficiency causes a bone dysplasia with autoimmunity and a type I interferon expression signature. Nat. Genet. 2011, 43:127-131.
6. Chabas D., Baranzini S.E., Mitchell D., Bernard C.C., Rittling S.R., Denhardt D.T., Sobel R.A., Lock C., Karpuj M., Pedotti R., Heller R., Oksenberg J.R., Steinman L. The influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease. Science 2001, 294:1731-1735.
7. Chen G., Zhang X., Li R., Fang L., Niu X., Zheng Y., He D., Xu R., Zhang J.Z. Role of osteopontin in synovial Th17 differentiation in rheumatoid arthritis. Arthritis Rheum. 2010, 62:2900-2908.
8. Compston A., Coles A. Multiple sclerosis. Lancet 2008, 372:1502-1517.
9. Giachelli C.M., Lombardi D., Johnson R.J., Murry C.E., Almeida M. Evidence for a role of osteopontin in macrophage infiltration in response to pathological stimuli in vivo. Am. J. Pathol. 1998, 152:353-358.
10. Hengstman G.J., Wesseling P., Frenken C.W., Jongen P.J. Neuromyelitis optica with clinical and histopathological involvement of the brain. Mult. Scler. 2007, 13:679-682.
11. Ishizu T., Osoegawa M., Mei F.J., Kikuchi H., Tanaka M., Takakura Y., Minohara M., Murai H., Mihara F., Taniwaki T., Kira J. Intrathecal activation of the IL-17/IL-8 axis in opticospinal multiple sclerosis. Brain 2005, 128:988-1002.
12. Jarius S., Paul F., Franciotta D., Waters P., Zipp F., Hohlfeld R., Vincent A., Wildemann B. Mechanisms of disease: aquaporin-4 antibodies in neuromyelitis optica. Nat. Clin. Pract. Neurol. 2008, 4:202-214.
13. Kaleta B. Role of osteopontin in systemic lupus erythematosus. Arch. Immunol. Ther. Exp. 2014, 11:11.
14. Kariya Y., Kanno M., Matsumoto-Morita K., Konno M., Yamaguchi Y., Hashimoto Y. Osteopontin O-glycosylation contributes to its phosphorylation and cell-adhesion properties. Biochem. J. 2014, 463:93-102. 10.1042/BJ20140060.
15. Kazanecki C.C., Uzwiak D.J., Denhardt D.T. Control of osteopontin signaling and function by post-translational phosphorylation and protein folding. J. Cell. Biochem. 2007, 102:912-924.
16. Lausch E., et al. Genetic deficiency of tartrate-resistant acid phosphatase associated with skeletal dysplasia, cerebral calcifications and autoimmunity. Nat. Genet. 2011, 43:132-137.
17. Lennon V.A., Wingerchuk D.M., Kryzer T.J., Pittock S.J., Lucchinetti C.F., Fujihara K., Nakashima I., Weinshenker B.G. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004, 364:2106-2112.
18. Lucchinetti C.F., Mandler R.N., McGavern D., Bruck W., Gleich G., Ransohoff R.M., Trebst C., Weinshenker B., Wingerchuk D., Parisi J.E., Lassmann H. A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. Brain 2002, 125:1450-1461.
19. Murugaiyan G., Mittal A., Weiner H.L. Increased osteopontin expression in dendritic cells amplifies IL-17 production by CD4+ T cells in experimental autoimmune encephalomyelitis and in multiple sclerosis. J. Immunol. 2008, 181:7480-7488.
20. Nishiyama S., Ito T., Misu T., Takahashi T., Kikuchi A., Suzuki N., Jin K., Aoki M., Fujihara K., Itoyama Y. A case of NMO seropositive for aquaporin-4 antibody more than 10years before onset. Neurology 2009, 72:1960-1961.
21. Shimizu Y., Yokoyama K., Misu T., Takahashi T., Fujihara K., Kikuchi S., Itoyama Y., Iwata M. Development of extensive brain lesions following interferon beta therapy in relapsing neuromyelitis optica and longitudinally extensive myelitis. J. Neurol. 2008, 255:305-307.
22. Singh R.P., Patarca R., Schwartz J., Singh P., Cantor H. Definition of a specific interaction between the early T lymphocyte activation 1 (Eta-1) protein and murine macrophages in vitro and its effect upon macrophages in vivo. J. Exp. Med. 1990, 171:1931-1942.
23. Sodek J., Ganss B., McKee M.D. Osteopontin. Crit. Rev. Oral Biol. Med. 2000, 11:279-303.
24. Vogt M.H., Lopatinskaya L., Smits M., Polman C.H., Nagelkerken L. Elevated osteopontin levels in active relapsing-remitting multiple sclerosis. Ann. Neurol. 2003, 53:819-822.
25. Vogt M.H., ten Kate J., Drent R.J., Polman C.H., Hupperts R. Increased osteopontin plasma levels in multiple sclerosis patients correlate with bone-specific markers. Mult. Scler. 2010, 16:443-449.
26. Wang A.G., Lin Y.C., Wang S.J., Tsai C.P., Yen M.Y. Early relapse in multiple sclerosis-associated optic neuritis following the use of interferon beta-1a in Chinese patients. Jpn. J. Ophthalmol. 2006, 50:537-542.
27. Warabi Y., Matsumoto Y., Hayashi H. Interferon beta-1b exacerbates multiple sclerosis with severe optic nerve and spinal cord demyelination. J. Neurol. Sci. 2007, 252:57-61.
28. Wingerchuk D.M., Lennon V.A., Lucchinetti C.F., Pittock S.J., Weinshenker B.G. The spectrum of neuromyelitis optica. Lancet Neurol. 2007, 6:805-815.
29. Xanthou G., Alissafi T., Semitekolou M., Simoes D.C., Economidou E., Gaga M., Lambrecht B.N., Lloyd C.M., Panoutsakopoulou V. Osteopontin has a crucial role in allergic airway disease through regulation of dendritic cell subsets. Nat. Med. 2007, 13:570-578. (Epub 2007 Apr 2015).
30. Yumoto K., Ishijima M., Rittling S.R., Tsuji K., Tsuchiya Y., Kon S., Nifuji A., Uede T., Denhardt D.T., Noda M. Osteopontin deficiency protects joints against destruction in anti-type II collagen antibody-induced arthritis in mice. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:4556-4561.